STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Form 144 reports restricted stock vesting and immediate sale of 3,731 shares

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

The filing is a Form 144 reporting a proposed sale of 3,731 shares of common stock with an aggregate market value of $417,872. The securities are listed as outstanding in the amount of 60,658,809 shares and the proposed sale is identified for 08/08/2025 on NASDAQ.

The shares were acquired on 08/07/2025 as restricted stock vesting from the issuer and the consideration is listed as compensation. The form notes "Nothing to Report" for securities sold during the past three months. Several filer contact fields (including CIK and submission contact details) appear blank in the provided content.

Positive

  • Transaction is small relative to outstanding shares (3,731 of 60,658,809, ≈0.006%), implying limited market impact
  • Securities were acquired as compensation via restricted stock vesting, a routine corporate compensation mechanism

Negative

  • Planned sale occurs one day after vesting (acquired 08/07/2025; approximate sale 08/08/2025), which may attract attention to timing
  • Filer identification and contact fields are blank in the provided content, a gap in the extracted filing information

Insights

TL;DR: A small, routine insider-related sale: 3,731 shares worth $417,872, representing roughly 0.006% of outstanding stock.

The transaction size is immaterial to market capitalization given 3,731 shares versus 60,658,809 outstanding (≈0.006%). The filing shows the shares were acquired via restricted stock vesting and are being sold the next day, producing $417,872 of aggregate value. No prior sales by the person are reported in the last three months. From a financial-impact perspective, this disclosure is routine and unlikely to move investor valuation.

TL;DR: Governance signals are routine but immediate post-vesting sale is notable for timing; disclosure appears complete except for missing filer contact details.

The filing documents a sale of shares that were vested as compensation and scheduled for sale the following day, which is an explicit timing fact in the notice. The form states no securities sold in the prior three months, suggesting this is a discrete transaction tied to granted compensation. However, filer identification and contact fields in the provided content are blank, which is a disclosure deficiency in the supplied document extract.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Form 144 report for JAZZ (metadata symbol)?

The provided Form 144 content reports a proposed sale of 3,731 common shares (aggregate value $417,872) identified in the filing as issued by ETRADE FINANCIAL CORPORATION; the metadata symbol JAZZ appears to differ from the issuer named in the filing content.

How many shares and what dollar value are scheduled for sale?

The notice lists 3,731 shares with an aggregate market value of $417,872.

When were the shares acquired and how were they acquired?

The shares were acquired on 08/07/2025 by restricted stock vesting from the issuer; the nature of payment is listed as compensation.

On which exchange is the sale planned?

The filing identifies the NASDAQ as the securities exchange for the proposed sale.

Were any securities sold by this person in the past three months?

The filing states "Nothing to Report" for securities sold during the past three months.
Jazz Pharmaceuticals Plc

NASDAQ:JAZZ

JAZZ Rankings

JAZZ Latest News

JAZZ Latest SEC Filings

JAZZ Stock Data

10.02B
58.92M
3.11%
105.97%
9.42%
Biotechnology
Pharmaceutical Preparations
Link
Ireland
DUBLIN